Form 4: Arcus Biosciences CFO Sells Shares to Cover Tax Obligations

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold 10,099 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Robert C. Goeltz II, the Chief Financial Officer of Arcus Biosciences, sold 10,099 shares of common stock on December 15, 2024.
• The sale was executed at a price of $16.08 per share.
• This transaction was a 'net settlement' by the company to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, Mr. Goeltz directly owns 63,732 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for companies to withhold shares to cover taxes when RSUs vest.

Comparison to Industry Standards

• Net settlement of RSUs for tax purposes is a standard practice across publicly traded companies.
• Executive stock sales are common and are often disclosed via SEC Form 4 filings.
• The number of shares sold is relatively small compared to the total outstanding shares of the company, and is not unusual for a CFO.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Arcus Biosciences, Robert C. Goeltz II, CFO, stock sale, Form 4, insider trading, restricted stock units, tax obligations, net settlement